Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 4:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 318 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Hepatitis B Infection Clear all
Terminated No phase listed Observational

Viral & Host Factors Associated With Hepatitis B Virus-related Hepatocellular Carcinoma

NCT00767936
View directory record Official record
Conditions
Liver Cancer, Hepatitis B, Hepatitis C, Hepatobiliary Cancers Liver, Hepatobiliary Cancers
Interventions
Not listed
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older · Male only
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 29, 2016 · Synced Oct 31, 2026, 4:05 PM EDT
Recruiting Phase 1 Interventional

Phase 1 Study to Evaluate Safety and Antiviral Activity of PBGENE-HBV in Adult Patients With Chronic Hepatitis B

NCT06680232
View directory record Official record
Conditions
HEPATITIS B CHRONIC
Interventions
PBGENE-HBV
Biological
Lead sponsor
Precision BioSciences, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 31, 2026, 4:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Study of GSK3228836 Pharmacokinetics in Participants With Hepatic Impairment

NCT04971928
View directory record Official record
Conditions
Hepatitis B
Interventions
GSK3228836
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
2
States / cities
Orlando, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 27, 2022 · Synced Oct 31, 2026, 4:05 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

VaxTeen Hepatitis B Vaccine Booster Study

NCT00144313
View directory record Official record
Conditions
Hepatitis
Interventions
hepatitis B vaccine
Biological
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
13 Years to 16 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
Anchorage, Alaska
Source: ClinicalTrials.gov public record
Updated Sep 21, 2007 · Synced Oct 31, 2026, 4:05 PM EDT
Completed Phase 4 Interventional Results available

A Study Of Maraviroc In HIV Co-Infected Subjects With Hepatitis C And/Or Hepatitis B

NCT01327547
View directory record Official record
Conditions
HIV Coinfection
Interventions
Maraviroc, Placebo
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
24
States / cities
Bakersfield, California • Los Angeles, California • Oakland, California + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2017 · Synced Oct 31, 2026, 4:05 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Adaptability of an Undetectable = Untransmissible Model for HBV

NCT07449091
View directory record Official record
Conditions
Chronic Hepatitis b, Viremia
Interventions
Not listed
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 65 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 31, 2026, 4:05 PM EDT
Completed Phase 1 Interventional

Activity of NCO-48 Fumarate in Treatment-Naive Adults With Chronic Hepatitis B

NCT04629976
View directory record Official record
Conditions
Chronic Hepatitis B
Interventions
NCO-48 Fumarate 4 mg, NCO-48 Fumarate 20 mg, Tenofovir Alafenamide 25 mg
Drug
Lead sponsor
Nucorion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Monterey Park, California
Source: ClinicalTrials.gov public record
Updated Jan 4, 2023 · Synced Oct 31, 2026, 4:05 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of Entecavir in Pediatric Patients With Chronic Hepatitis B Virus (HBV)-Infection

NCT00423891
View directory record Official record
Conditions
Hepatitis B, Chronic
Interventions
Entecavir
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
2 Years to 18 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
9
States / cities
San Francisco, California • Hartford, Connecticut • Gainesville, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated May 2, 2018 · Synced Oct 31, 2026, 4:05 PM EDT
Recruiting Phase 2 Interventional

Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States

NCT05832229
View directory record Official record
Conditions
Cirrhosis, Cirrhosis, Liver, Cirrhosis Early, Cirrhosis Due to Hepatitis B, Cirrhosis Advanced, Cirrhosis Infectious, Cirrhosis Alcoholic, Cirrhosis Due to Hepatitis C
Interventions
Rosuvastatin
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 75 Years
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
13
States / cities
La Jolla, California • Los Angeles, California • San Francisco, California + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 31, 2026, 4:05 PM EDT
Completed Phase 2 Interventional

Adefovir Dipivoxil to Treat Hepatitis B in HIV-Infected Patients

NCT00013702
View directory record Official record
Conditions
Hepatitis B, HIV Infection
Interventions
Adefovir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 31, 2026, 4:05 PM EDT
Withdrawn No phase listed Observational

The Regression of Liver Fibrosis and Risk for Hepatocellular Carcinoma (ROLFH) Study

NCT01831037
View directory record Official record
Conditions
Chronic Hepatitis C, Chronic Hepatitis B
Interventions
Regression of fibrosis, Specific risk factors related to hepatocellular carcinoma
Other
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
2
States / cities
Little Rock, Arkansas • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 28, 2015 · Synced Oct 31, 2026, 4:05 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Pentavalent DTaP-Hep B-IPV

NCT00133445
View directory record Official record
Conditions
Diphtheria, Hepatitis B, Poliomyelitis, Pertussis, Tetanus
Interventions
DTaP-Hep B-IPV Vaccine, Monovalent Hep B Vaccine, Placebo
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Up to 5 Days
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Nov 7, 2011 · Synced Oct 31, 2026, 4:05 PM EDT
Approved For Marketing No phase listed Expanded access

Treatment on HBeAg Positive or HBeAg Negative in Chronic Hepatitis B

NCT01198860
View directory record Official record
Conditions
CHRONIC HEPATITIS B
Interventions
CTH Chronic Hepatitis B
Drug
Lead sponsor
Nguyen Thi Trieu, MD
Individual
Eligibility
18 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Wilmington, Delaware
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Oct 31, 2026, 4:05 PM EDT
Withdrawn Not applicable Interventional

Abatacept vs Placebo in RA Patients With Hepatitis B on Entecavir Background

NCT02053727
View directory record Official record
Conditions
Rheumatoid Arthritis, Chronic Hepatitis B
Interventions
Abatacept, Placebo
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 16, 2020 · Synced Oct 31, 2026, 4:05 PM EDT
Not yet recruiting Phase 3 Interventional Accepts healthy volunteers

Duo: A Phase IIIb Individual-Level Randomized Controlled Trial of an Integrated Strategy

NCT07658976
View directory record Official record
Conditions
HIV Infection, Sexually Transmitted Infection
Interventions
HIV PrEP - choice of F/TDF, F/TAF, or CAB-LA, STI PEP - Doxycycline as Doxy-PEP, 3P mHealth package, Handout about HIV PrEP options available at the site, Standard-of-care HIV PrEP counseling from qualified study staff
Drug · Behavioral
Lead sponsor
HIV Prevention Trials Network
Network
Eligibility
18 Years to 29 Years · Male only
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
2
States / cities
Los Angeles, California • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 31, 2026, 4:05 PM EDT
Completed Phase 3 Interventional Results available

Comparison of Entecavir to Adefovir in Chronic Hepatitis B Virus (HBV) Patients With Hepatic Decompensation

NCT00065507
View directory record Official record
Conditions
Hepatitis B
Interventions
Entecavir (ETV), Adefovir (ADV)
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
16 Years and older
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2013
U.S. locations
16
States / cities
San Diego, California • San Francisco, California • New Haven, Connecticut + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2013 · Synced Oct 31, 2026, 4:05 PM EDT
Completed Not applicable Interventional

Pneumococcal Vaccine and Routine Pediatric Immunizations in HIV-Infected Children Receiving Anti-HIV Drugs

NCT00013871
View directory record Official record
Conditions
HIV Infections, Hepatitis B, Measles, Pneumococcal Infections, Pertussis
Interventions
Diphtheria & Tetanus Toxoids & Acellular Pertussis Vaccine Adsorbed, Measles-Mumps-Rubella Vaccine (Live), Pneumococcal Vaccine, Polyvalent (23-valent), Pneumococcal Conjugate Vaccine, Heptavalent, Hepatitis B Vaccine (Recombinant)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years to 18 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2004
U.S. locations
38
States / cities
Birmingham, Alabama • Long Beach, California • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 31, 2026, 4:05 PM EDT
Terminated Phase 3 Interventional Results available

Prophylactic Antiviral Therapy in Patients With Current or Past Hepatitis B Virus Infection Receiving Anti-Cancer Therapy for Solid Tumors

NCT03887702
View directory record Official record
Conditions
Hepatitis B Infection, Malignant Solid Neoplasm
Interventions
Best Practice, Entecavir, Tenofovir Alafenamide, Tenofovir Disoproxil Fumarate
Other · Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
192
States / cities
Fort Smith, Arkansas • Anaheim, California • Antioch, California + 140 more
Source: ClinicalTrials.gov public record
Updated May 20, 2024 · Synced Oct 31, 2026, 4:05 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Patient-Centered Care and Asian Americans

NCT02139722
View directory record Official record
Conditions
Hepatitis B, Hepatitis C, Liver Disease
Interventions
Video Doctor, PA + PPN
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
431 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
2
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 21, 2020 · Synced Oct 31, 2026, 4:05 PM EDT
Not listed Phase 2 Interventional

A Phase II Study to Determine the Safety and Efficacy of Interferon-gamma in Patients With Chronic Hepatitis B

NCT00753467
View directory record Official record
Conditions
Hepatitis B
Interventions
IFN-γ 1b (Actimmune), Adefovir dipivoxil, IFN-γ 1b and Adefovir dipivoxil combination
Drug
Lead sponsor
Huntington Medical Research Institutes
Other
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Pasadena, California
Source: ClinicalTrials.gov public record
Updated Oct 21, 2010 · Synced Oct 31, 2026, 4:05 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Safety and Efficacy of Switching to Tenofovir Alafenamide (TAF) From Tenofovir Disoproxil Fumarate (TDF) and/or Other Oral Antiviral Treatment (OAV)

NCT03180619
View directory record Official record
Conditions
Chronic Hepatitis B
Interventions
TAF
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
4
States / cities
Los Angeles, California • San Jose, California • Detroit, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2021 · Synced Oct 31, 2026, 4:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Mass Balance Absorption and AME of VBR

NCT04637139
View directory record Official record
Conditions
Chronic Hepatitis B
Interventions
Vebicorvir (VBR)
Drug
Lead sponsor
Assembly Biosciences
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 12, 2021 · Synced Oct 31, 2026, 4:05 PM EDT
Completed Phase 3 Interventional Results available

Entecavir Plus Adefovir Combination Therapy Versus Entecavir Monotherapy vs Therapy With Adefovir Plus Lamivudine for Chronic Hepatitis B Infected Subjects With Lamivudine-resistant Virus

NCT00410202
View directory record Official record
Conditions
Hepatitis B, Chronic
Interventions
Entecavir, Tenofovir, Adefovir, Lamivudine
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
16 Years and older
Enrollment
629 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 21, 2013 · Synced Oct 31, 2026, 4:05 PM EDT
Completed Phase 4 Interventional Results available

A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Hepatitis Be Antigen (HBeAg) Positive Chronic Hepatitis B (CHB).

NCT00435825
View directory record Official record
Conditions
Hepatitis B, Chronic
Interventions
peginterferon alfa-2a [Pegasys]
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
551 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
10
States / cities
Los Angeles, California • Palo Alto, California • San Diego, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2013 · Synced Oct 31, 2026, 4:05 PM EDT